What Is Palmitoyl Tripeptide-1? Benefits, Research & Safety
A lipopeptide signal peptide that mimics collagen breakdown fragments to stimulate new collagen and elastin production for anti-ageing skincare.
UK summary: Cosmetic peptide (lipopeptide form of GHK) regulated under UK cosmetics legislation. Component of the Matrixyl 3000 complex. Topical only.
Quick Facts
Overview
Palmitoyl Tripeptide-1 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Cosmetic peptide (lipopeptide form of GHK) regulated under UK cosmetics legislation. Component of the Matrixyl 3000 complex. Topical only.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Regulated as a cosmetic ingredient. Widely available in skincare products without prescription.
- EU: Listed in the EU cosmetic ingredient database (CosIng). Permitted in cosmetic formulations.
- Notes: Classified as a cosmetic ingredient globally. Not a pharmaceutical or research peptide. Widely used in commercial anti-ageing products.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Equivalent to medical anti-ageing treatments.
- Injectable use is safe.
07Common internet claims
- Marketed in finished cosmetic skincare; component of the Matrixyl 3000 complex.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Stimulates collagen synthesis topically” | C | Yes | Low | Manufacturer-led human trials of formulations containing Palmitoyl Tripeptide-1 show measurable skin-elasticity improvements. |
09Safety uncertainty score
Safety profile is well-characterised in published human data.
10Known adverse signals
- Generally well-tolerated topically.
- Rare skin sensitivity.
11Drug-interaction uncertainty
Drug-interaction picture documented in the prescribing information.
12Anti-doping status
13UK legal position
Regulated as a cosmetic ingredient. Widely available in skincare products without prescription.
14EU legal position
Listed in the EU cosmetic ingredient database (CosIng). Permitted in cosmetic formulations.
15What this page cannot tell you
- Whether a particular finished product contains the labelled concentration.
- Real-world effect magnitude vs topical retinoid.
16Last reviewed
17Citation quality score
18Research gaps
- Independent comparative-effectiveness trials limited.
19Safer alternatives / established care pathways
- Sunscreen + topical retinoid as foundation skincare.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is this an appropriate addition to my skincare routine?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Stimulation of Type I collagen synthesis in fibroblasts
- 2Visible reduction in wrinkle depth in clinical studies
- 3Improvement in skin firmness and elasticity
- 4Enhanced extracellular matrix production
- 5Synergistic effects when combined with Palmitoyl Tetrapeptide-7 (Matrixyl 3000)
- 6Good skin tolerability with minimal irritation potential
Claim vs Evidence
How popular claims about Palmitoyl Tripeptide-1 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Stimulates collagen synthesis topically” | C | Yes | Low | Manufacturer-led human trials of formulations containing Palmitoyl Tripeptide-1 show measurable skin-elasticity improvements. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Typical concentration in skincare: 2-5% of the peptide complex (Matrixyl 3000) |
| Frequency | Twice daily application (morning and evening) |
| Duration | Clinical studies typically 2-4 months; ongoing use for maintained benefits |
| Notes | Applied topically as part of serum or moisturiser formulations. Best results with consistent, long-term use. Often combined with Palmitoyl Tetrapeptide-7 and other active ingredients. |
Administration Routes
Routes studied in research settings (educational only):
- Topical (serums, creams, moisturisers)
| Half-Life | Stability |
|---|---|
| Topical application; systemic pharmacokinetics not relevant. Effects depend on continuous application. | Stable in properly formulated cosmetic products. Protected from excessive heat and light. |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Very well tolerated
- Rare mild skin irritation in sensitive individuals
Rare Risks & Concerns
- Allergic contact dermatitis (very rare)
- Not associated with systemic side effects
Contraindications
- Known hypersensitivity to the ingredient
- Open wounds or broken skin (apply to intact skin only)
UK & EU Regulatory Context
🇬🇧 United Kingdom
Regulated as a cosmetic ingredient. Widely available in skincare products without prescription.
🇪🇺 European Union
Listed in the EU cosmetic ingredient database (CosIng). Permitted in cosmetic formulations.
Clinical Studies Summary
Matrixyl 3000 Clinical Efficacy Study
Clinical trial demonstrated that 2-month application of Matrixyl 3000 (Palmitoyl Tripeptide-1 + Palmitoyl Tetrapeptide-7) reduced wrinkle volume by up to 44% compared to baseline, with significant improvements in skin firmness and smoothness.
In Vitro Collagen Stimulation
Cell culture studies demonstrated that Palmitoyl Tripeptide-1 significantly increased Type I collagen production by human dermal fibroblasts in a dose-dependent manner, confirming the matrikine signalling mechanism.
Looking for Palmitoyl Tripeptide-1?
Source research-grade Palmitoyl Tripeptide-1 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Palmitoyl Tripeptide-1
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is this an appropriate addition to my skincare routine?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Combination Protocols
Related Peptides
GHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreMatrixyl
A pioneering signal peptide that mimics natural collagen-boosting messengers, extensively validated in clinical studies for wrinkle reduction and skin firmness improvement.
Learn moreArgireline
A neuromodulating hexapeptide that reduces facial muscle contractions through SNARE complex inhibition, providing a topical alternative to botulinum toxin for expression line reduction.
Learn moreSNAP-8
An enhanced 8-amino acid version of Argireline with improved penetration and efficacy for reducing expression lines through SNARE complex modulation.
Learn moreSyn-Ake
A tripeptide that mimics the neuromuscular blocking effects of Temple Viper venom (waglerin-1), targeting nicotinic acetylcholine receptors to reduce expression lines.
Learn more